Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates

Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year

Sun Pharmaceuticals on Thursday said that China and Japan are becoming increasingly important markets for growth. It posted its second quarter results, mostly in line with Street expectations, with pre-tax profit of Rs 1,433.38 crore, against Rs 111.94 crore last year, which was impacted by settlements related to an antitrust litigation concerning Modafinil in the US. 

Sun Pharma has been working on forging partnerships for China. On Wednesday, it announced a licensing agreement with AstraZeneca UK to introduce certain novel ready-to-use infusion oncology products in China. Speaking to analysts during the earnings call, Managing Director Dilip Shanghvi said: “The focus